Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a health diagnostics company headquartered in Salt Lake City, Utah, focused on precision pregnancy care and the early prediction of spontaneous preterm birth. News about Sera often centers on its PreTRM® Test, a blood-based biomarker test that provides individualized risk prediction for preterm birth in asymptomatic singleton pregnancies, and on the growing clinical and payer interest in this approach.
On this page, readers can find updates on Sera’s clinical research, including results and publications from the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study. Company press releases describe how the PRIME randomized controlled trial evaluated the PreTRM Test combined with targeted interventions and reported reductions in very early preterm births, NICU admissions, neonatal complications, and NICU length of stay compared with standard care.
SERA news coverage also includes quarterly financial results, payer and Medicaid pilot initiatives, and commentary on commercial progress for the PreTRM Test. The company has highlighted engagement with Medicaid plans and other organizations in multiple states, as well as presentations at medical and investor conferences where leadership discusses clinical data, health economic analyses, and market adoption efforts.
Investors and healthcare professionals following SERA can use this news feed to review announcements related to leadership appointments, conference presentations, regulatory filings summarized in press releases, and ongoing work to position pregnancy biomarker testing within prenatal care. Bookmark this page to access a consolidated view of Sera Prognostics’ latest press releases, study milestones, and business updates connected to its focus on improving outcomes for mothers and newborns.
Sera Prognostics (NASDAQ: SERA) reported PRIME, a randomized trial of 5,018 women published Jan 7, 2026 in PREGNANCY, showing the PreTRM blood test plus targeted interventions reduced earliest preterm births and newborn complications.
Key results: 56% fewer births before 32 weeks, 32% fewer before 35 weeks, 20% fewer NICU admissions, and a 20% reduction in odds of neonatal morbidity. The study found one NICU day saved per 4.2 patients screened and a number-needed-to-screen of 39 to prevent one NICU admission.
Sera Prognostics (NASDAQ: SERA) announced that the PRIME study — Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs — was accepted for publication in a peer-reviewed medical journal on Nov. 24, 2025. The study is described as one of the largest preterm birth studies and its abstract was previously selected as a late-breaking abstract for podium presentation at the Society for Maternal-Fetal Medicine annual meeting earlier in 2025. Management said they will share the PRIME manuscript data upon publication and present findings at upcoming medical meetings and events with research analysts.
Sera Prognostics (Nasdaq: SERA) reported third quarter 2025 results for the period ended Sept 30, 2025, highlighting early commercial progress and PRIME study momentum.
Key points: Q3 revenue $16,000 vs $29,000 year-ago; deferred revenue +$100,000 from a Nevada Medicaid pilot prepayment; total operating expenses $9.0M; net loss $7.8M; and cash and securities ~$102.4M, which the company expects to fund operations through 2028. Company said PRIME data and health-economics results will publish this year and cited a 20% reduction in NICU admissions tied to PreTRM in presentations. Management noted payer discussions across 13 states and the launch of an actively enrolling Medicaid pilot in Nevada.
Sera Prognostics (Nasdaq:SERA) announced it will report third quarter fiscal 2025 financial results on Thursday, November 13, 2025 after market close.
The company will host a conference call and live webcast to discuss operational highlights and financial results at 5:00 p.m. Eastern Time. A press release with results and highlights will be distributed before the call. US callers: (800) 836-8184; international callers: (646) 357-8785. Webcast registration: https://app.webinar.net/1qop01GkwO2. Live audio and a webcast archive will be available on the Investors page at www.sera.com and the webcast will be archived for one year.
Sera Prognostics (NASDAQ:SERA) has appointed Dr. Tiffany Inglis as Chief Medical Officer. Dr. Inglis, who previously held clinical leadership positions at Elevance Health and Carelon Health, brings extensive experience in women's and children's health programs.
As a former practicing OBGYN with over a decade of experience, Dr. Inglis will lead Sera's clinical operations to advance the company's position in women's health diagnostics, particularly focusing on the PreTRM® Test. Her appointment comes at a crucial time as the company prepares for the publication of the PRIME study and launches pilots with state Medicaid programs.
Dr. Inglis received her medical degree from the Medical College of Ohio in 2002 and completed her Obstetrics and Gynecology residency at Riverside Methodist Hospital in 2006. Her expertise includes implementing cost-effective solutions for improving maternal and neonatal outcomes.
Sera Prognostics (Nasdaq: SERA), known as The Pregnancy Company®, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's President and CEO, Zhenya Lindgardt, will deliver a corporate presentation on September 5, 2025, at 7:00 a.m. ET.
The conference, scheduled for September 8-10, 2025 in New York City, will include one-on-one investor meetings. Investors can access both the live presentation and replay through the Investors section of Sera's website at www.sera.com.
Sera Prognostics (NASDAQ: SERA) reported its Q2 2025 financial results, showing revenue of $17,000, down from $24,000 in Q2 2024. The company recorded a net loss of $8.0 million, slightly improved from $8.3 million in the prior year.
Operating expenses remained flat at $9.3 million, with R&D expenses decreasing 24% to $3.3 million while SG&A expenses increased to $6.0 million. The company maintains a strong financial position with $108.5 million in cash and securities, expected to fund operations through 2028.
Sera strengthened its leadership team with key appointments, including Lee Anderson as Chief Commercial Officer, Chuck Hyde as Head of Market Access, and Jennifer Zibuda as Head of Investor Relations. The company is progressing with Medicaid plan engagement and preparing to publish full results of its PRIME study.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has scheduled its second quarter fiscal year 2025 financial results announcement for August 6, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights and financial results.
Investors can access the conference call via US domestic line (800) 836-8184 or international line (646) 357-8785. A live webcast will be available on the company's investor relations website, with a one-year archive period.
Sera Prognostics (Nasdaq: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, announced its participation in two major investor conferences in June 2025:
At the William Blair 45th Annual Growth Stock Conference (June 3-5), Dr. Doug Fisher, Strategic Advisor and former Chief Business Officer, will conduct one-on-one meetings on June 4. At the Jefferies Global Healthcare Conference (June 3-5), President and CEO Zhenya Lindgardt and CFO Austin Aerts will participate in meetings, with Lindgardt delivering a presentation on June 4 from 3:10-3:40 PM ET to provide company updates and discuss recent achievements. The Jefferies presentation will be available via live webcast and replay on Sera's investor website.
Sera Prognostics (Nasdaq: SERA), known as The Pregnancy Company®, has announced its participation in the upcoming RBC Global Healthcare Conference. The company's President and CEO, Zhenya Lindgardt, will engage in a fireside chat on May 21, 2025, from 9:30 to 9:55 AM ET. During the presentation, Lindgardt will provide updates on the company and discuss its recent achievements. The presentation will be accessible via live webcast and replay through the Investors section of Sera's website at www.sera.com.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
